Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma
This study seeks to evaluate the safety and pharmacokinetics of duvelisib in Japanese participants with relapsed or refractory lymphoma.
Lymphoma
DRUG: duvelisib
Number of participants reporting Treatment-emergent Adverse Events, The number of participants reporting treatment-emergent adverse events., Throughout the study for approximately 2 years|Maximum Observed Plasma Concentration (Cmax) of Duvelisib, Cycle 1 Day 1, 8, 15, and 22 and on Day 1 of Cycles 2 - 5|Time to Maximum Observed Concentration (Tmax) of Duvelisib, Cycle 1 Day 1, 8, 15, and 22 and on Day 1 of Cycles 2 - 5|Area Under the Plasma Concentration-time Curve (AUC) of Duvelisib, Cycle 1 Day 1, 8, 15, and 22 and on Day 1 of Cycles 2 - 5
Overall Response Rate, Overall Response Rate is defined as the proportion of participants with a confirmed response of complete (CR) or partial response (PR) based on the revised International Working Group (IWG) criteria., Throughout the study for approximately 2 years|Overall Survival, Overall survival is defined as the duration in weeks from the date of the first dose of study treatment until the date of death., Throughout the study for approximately 2 years|Progression Free Survival, Progression free survival is defined as the time from the date of the first dose of study treatment to the first documentation of progressive disease (PD) or death due to any cause., Throughout the study for approximately 2 years
This study seeks to evaluate the safety and pharmacokinetics of duvelisib in Japanese participants with relapsed or refractory lymphoma.